BNTC — Benitec Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $18.12m
- -$2.25m
- $0.08m
- 21
- 12
- 100
- 40
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | 10-K | 10-K | 10-K | 10-K |
Standards: | IFRS | USG | USG | USG | USG |
Status: | fx Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 11.9 | 0.102 | 0.059 | 0.073 | 0.075 |
Cost of Revenue | |||||
Gross Profit | 11.4 | 0.287 | -0.064 | 0.064 | 0.075 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 9.61 | 8.38 | 13.7 | 17.9 | 19.2 |
Operating Profit | 2.26 | -8.28 | -13.6 | -17.9 | -19.1 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.93 | -8.27 | -13.9 | -18.2 | -19.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.93 | -8.27 | -13.9 | -18.2 | -19.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 2.93 | -8.27 | -13.9 | -18.2 | -19.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.93 | -8.27 | -13.9 | -18.2 | -19.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.291 | -138 | -54.9 | -37.9 | -14.1 |